INTRODUCTION AND OBJECTIVES: Autoantibodies against peptides derived from prostate-cancer tissue have demonstrated utility in prostate cancer detection (New England Journal of Medicine: 2005; 353:1224-35) . Indeed, a commercially available test for prostate cancer detection, APIFINYâ, measures 8 such markers. We assessed the performance of a novel serum based multiplexed autoantibody assay using all 8 APIFINYâ markers along with an extended set up 13 new markers (21 markers total) plus standard of care (SOC) (PSA and age) vs. SOC alone for discriminating prostate cancer risk on biopsy as well as detecting high-grade prostate cancer on biopsy (Gleason Score (GS) 7 or greater).
METHODS: We compared the autoantibody assay with biopsy outcomes in 268 patients at risk of prostate cancer from two academic and one community clinical sites in the United States undergoing prostate biopsy. Eligible participants included cancer-free men, 40 years or older, scheduled for an initial or repeat prostate biopsy.
RESULTS: Among the 268 men (median age 62.4 yrs; median PSA 5.4 ng/mL), the autoantibody assay plus SOC showed better discrimination between prostate cancer from no cancer (AUC 0.73, 95%CI 0.67-0.79) vs. SOC alone (AUC 0.55, 95%CI 0.49-0.62) (P < 0.0001). Discrimination was high for separating GS7 or greater from GS6 and patients negative on biopsy (AUC 0.74, 95% CI 0.68-0.80) compared to SOC alone (AUC 0.61, 95% CI 0.54-0.68) (p < 0.001). Finally, for discrimination between GS7 or greater from GS 6 among patients who had positive biopsies, the autoantibody assay + SOC (AUC 0.83, 95% CI 0.76-0.90) was better than SOC alone (AUC 0.71, 95% CI 0.63-0.80) (p ¼ 0.001). A test developed with these biomarkers detected GS 6 or higher with 95.0% sensitivity and 25.2% specificity. For detected GS7 or higher test with 95% sensitivity, and 24.4% of unnecessary biopsies would have been avoided, missing only 4.9% of patients with GS7 disease.
CONCLUSIONS: This expanded serum based multiplexed autoantibody assay can accurately identify patients with prostate cancer and can identify patients with high grade disease better than the current SOC (age and PSA).
Source of Funding: Armune BioScience, Inc.
MP28-07 AN AUTOMATED-MICROCAPILLARY ELECTROPHORESIS-BASED IMMUNOASSAY SYSTEM MAY IMPROVE DIAGNOSTIC ACCURACY OF PROSTATE CANCER AND BE A GOOD INDICATOR OF GLEASON SCORE
Tomokazu Ishikawa*, Tohru Yoneyama, Yuki Tobisawa, Shingo Hatakeyama, Hirosaki, Japan; Tatsuo Kurosawa, Kenji Nakamura, Amagasaki, Japan; Takuya Koie, Yasuhiro Hashimoto, Chikara Ohyama, Hirosaki, Japan INTRODUCTION AND OBJECTIVES: Lack of specificity in PSA test for early detection of prostate cancer (PCa) is one of the major issues all over the world. Therefore, the development of novel assay system with improved specificity is urgently needed. We identified PCaassociated aberrant glycosylation of PSA (S2,3PSA) and developed an automated-microcapillary electrophoresis-based immunoassay system (mTAS method). Furthermore, we successfully applied this assay system for clinical setting.
METHODS: S2,3PSA was clearly differentiated by the lectin reactivity to recognize aberrant glycosylation on free PSA (fPSA) and calculate the ratio (%) in the microfluidic separation channel with fPSA antibody-label conjugates. We measured %S2,3PSA by utilizing mTAS method with extremely shortened assay time (9 min) and evaluated the cutoff values in biopsy proven patient samples (103 with PCa and 50 with non-PCa) including PSA less than 20.0 ng/ml. Receiver operating characteristic (ROC) curves were used to evaluate diagnostic accuracy for %S2,3PSA in comparison with other methods.
RESULTS: %S2,3PSA of PCa was significantly higher than those of non-PCa (p < 0.0001) and the appropriate cutoff value was determined to be 40% of S2,3PSA ratio in terms of diagnostic accuracy. The area under the curve (AUC) for the detection of PCa with %S2,3PSA ratio was 0.851, which was significantly more effective than that with total PSA (AUC; 0.658). And also, good correlation in this assay with Gleason score after radical prostatectomy (pGS) was suggested for the discrimination of high risk PCa. Especially, high-risk PCa patients with GS4+3 could be separated by the S2,3PSA percentage cut off of 50%, achieving a high performance (AUC; 0.921).
CONCLUSIONS: Although the present study is still preliminary, these results suggest that the newly developed serum %S2,3PSA test may contribute improved diagnostic accuracy having good correlation with prostatectomy Gleason score. Additional validation studies are warranted.
